The extensive global reach of Julius Clinical is demonstrated well by the ALECARDIO trial. The aim of the trial was to determine the effect of treatment with aleglitazar on cardiovascular mortality and morbidity (defined as non-fatal myocardial infarction or stroke) in patients with type 2 diabetes who experienced a recent acute coronary syndrome (ACS) event.